Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Abstract Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only a subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. Herein, we investigated patient subpopulations more lik...

Full description

Bibliographic Details
Main Authors: Song-Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wen-Tao Yang, Wen-Jun Chai, Xiao-Mao Guo, Xi-Zi Chen, Yan-Hui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Molecular Cancer
Subjects:
Triple-negative breast cancer
Immunomodulatory subtype
First-line treatment
Clinical trial
Combination immunotherapy
Predictive biomarker
Online Access:https://doi.org/10.1186/s12943-022-01536-6

Internet

https://doi.org/10.1186/s12943-022-01536-6

Similar Items